Literature DB >> 11256618

Certain promise and uncertain peril. The debate on xenotransplantation.

R A Weiss1.   

Abstract

Mesh：

Year:  2000        PMID： 11256618      PMCID： PMC1083692          DOI： 10.1093/embo-reports/kvd017

Source DB:  PubMed          Journal:  EMBO Rep        ISSN： 1469-221X            Impact factor:   8.807


× No keyword cloud information.
  10 in total

1.  The axis of interleukin 12 and gamma interferon regulates acute vascular xenogeneic rejection.

Authors:  H Wang; M E DeVries; S Deng; M H Khandaker; J G Pickering; L H Chow; B Garcia; D J Kelvin; R Zhong
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

2.  Xenotransplantation: Scientific Frontiers and Public Policy. Proceedings of a conference. New York, New York, USA. May 18-20, 1998.

Authors: 
Journal:  Ann N Y Acad Sci       Date:  1998-12-30       Impact factor: 5.691

3.  Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group.

Authors:  K Paradis; G Langford; Z Long; W Heneine; P Sandstrom; W M Switzer; L E Chapman; C Lockey; D Onions; E Otto
Journal:  Science       Date:  1999-08-20       Impact factor: 47.728

4.  Uncertainty in xenotransplantation: individual benefit versus collective risk.

Authors:  F H Bach; J A Fishman; N Daniels; J Proimos; B Anderson; C B Carpenter; L Forrow; S C Robson; H V Fineberg
Journal:  Nat Med       Date:  1998-02       Impact factor: 53.440

Review 5.  The alpha-galactosyl epitope: a sugar coating that makes viruses and cells unpalatable.

Authors:  R P Rother; S P Squinto
Journal:  Cell       Date:  1996-07-26       Impact factor: 41.582

Review 6.  Progress in xenotransplantation.

Authors:  E Cozzi; S Masroor; B Soin; C Vial; D J White
Journal:  Clin Nephrol       Date:  2000-04       Impact factor: 0.975

7.  Infection of human cells by an endogenous retrovirus of pigs.

Authors:  C Patience; Y Takeuchi; R A Weiss
Journal:  Nat Med       Date:  1997-03       Impact factor: 53.440

8.  Liver allotransplantation after extracorporeal hepatic support with transgenic (hCD55/hCD59) porcine livers: clinical results and lack of pig-to-human transmission of the porcine endogenous retrovirus.

Authors:  M F Levy; J Crippin; S Sutton; G Netto; J McCormack; T Curiel; R M Goldstein; J T Newman; T A Gonwa; J Banchereau; L E Diamond; G Byrne; J Logan; G B Klintmalm
Journal:  Transplantation       Date:  2000-01-27       Impact factor: 4.939

9.  Transgenic pigs and virus adaptation.

Authors:  R A Weiss
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

10.  Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results.

Authors:  J S Fink; J M Schumacher; S L Ellias; E P Palmer; M Saint-Hilaire; K Shannon; R Penn; P Starr; C VanHorne; H S Kott; P K Dempsey; A J Fischman; R Raineri; C Manhart; J Dinsmore; O Isacson
Journal:  Cell Transplant       Date:  2000 Mar-Apr       Impact factor: 4.064
  10 in total
  4 in total

Review 1.  Lentiviral transgene vectors.

Authors:  Reinhard Fässler
Journal:  EMBO Rep       Date:  2004-01       Impact factor: 8.807

2.  Isolation and characterization of an infectious replication-competent molecular clone of ecotropic porcine endogenous retrovirus class C.

Authors:  Thomas Preuss; Nicole Fischer; Klaus Boller; Ralf R Tönjes
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  HIV and AIDS in relation to other pandemics. Among the viruses plaguing humans, HIV is a recent acquisition. Its outstanding success as an infection poses immense scientific challenges to human health and raises the question "What comes nest?".

Authors:  Robin A Weiss
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

4.  Establishment of cell lines with increased susceptibility to EV71/CA16 by stable overexpression of SCARB2.

Authors:  Xiaojun Li; Peihu Fan; Jun Jin; Weiheng Su; Dong An; Lin Xu; Shiyang Sun; Yan Zhang; Xiangyu Meng; Feng Gao; Wei Kong; Chunlai Jiang
Journal:  Virol J       Date:  2013-08-06       Impact factor: 4.099
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.